News

Irinotecan is a generic chemotherapy agent, marketed in the US as Camptosar. In preclinical studies, Davanat has demonstrated it significantly improves irinotecan activity in the tumor as measured

The companies want the label to include additional information that Erbitux improves overall survival in the third-line treatment of patients with metastatic colorectal cancer The FDA has granted

The alliance combines Archemix’s proprietary Selex technology to discover and generate aptamer candidates with Merck’s demonstrated oncology drug development and commercialization capabilities, according to the companies. In addition

The goal of the trial was to develop a four-month formulation of triptorelin, the active ingredient in Decapeptyl, a treatment for hormone sensitive prostate cancer. Ipsen’s goal remains

Archemix plans to present a complete data set from this phase I clinical trial within a peer-reviewed forum in 2007. The drug, ARC1779, is designed to selectively block

The results were from the second of the two successful phase III placebo-controlled clinical trials evaluating the efficacy and safety of Frova in menstrual migraine (MM) prophylaxis. Women

The drug achieved the results without evidence of post operative residual curarization (PORC) or re-occurrence of muscle relaxation, Organon added. The trial compared the efficacy of sugammadex and

In this randomized, double-blind, placebo-controlled, parallel-group, multi-center outcomes trial, patients with acutely decompensated heart failure will be randomized to receive placebo or Natrecor for a minimum of 24

The phase I monthly sustained release implant study showed that the treatment, Debio 9902, was well tolerated after repeated doses up to 15mg/per month and there were no